Sharenet Sites 
Sharenet Sites
Results of General Meeting Proceedings
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen Holdings" or "the Company")
RESULTS OF GENERAL MEETING PROCEEDINGS
Shareholders are advised that, at the General Meeting of members held on Monday,15 August 2016,
a total of 278 345 192 or 60.99% of issued shares (456 403 819) were voted and that the further
voting statistics from this General Meeting are confirmed to be as follows:
1 Special resolution number 1: Amendment to the Memorandum of Incorporation
For Against Abstain Shares voted
276 576 556 0 1 768 636 278 345 192
100.00% 0.00% - 100.00%
2 Ordinary resolution number 1: Re-election of John Buchanan as a director
For Against Abstain Shares voted
269 478 328 7 098 228 1 768 636 278 345 192
97.43% 2.57% - 97.43%
Johannesburg
16 August 2016
Sponsor
Investec Bank Limited
About Aspen
Aspen is a leading global player in specialty and generic pharmaceuticals with an extensive basket of products that
provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. Aspen
continues to increase the number of lives benefitting from its products, reaching more than 150 countries.
Aspen has a strong presence in both emerging and developed countries. Its emerging market footprint includes Sub-
Saharan Africa (where it is the largest pharmaceutical company), Latin America, South East Asia, Eastern Europe and
the Commonwealth of Independent States, comprising Russia and the former Soviet Republics. From a developed world
perspective Aspen is one of the leading pharmaceutical companies in Australia and has a growing presence in other
developed countries, most notably in Western Europe.
Aspen operates with an established business presence in approximately 50 countries spanning 6 continents and
employs more than 10,000 people. The Group operates 26 manufacturing facilities across 18 sites. Aspen holds
international manufacturing approvals from some of the most stringent global regulatory agencies including the FDA,
TGA and EMA. Aspen’s manufacturing capabilities are scalable to demand and cover a wide variety of product-types
including oral solid dose, liquids, semi-solids, steriles, biologicals, active pharmaceutical ingredients and infant
nutritionals.
Aspen, with a market cap of approximately $13 billion, is the largest pharmaceutical company listed on the JSE Limited
(share code: APN) and ranks amongst the top 20 listed companies on this exchange. For more information visit:
http://www.aspenpharma.com/
Date: 16/08/2016 04:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
